Drug reference

edoxaban

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Drug class

Cardiovascular (Anti Thrombotics)

Mechanism of action

Factor Xa (FXa) inhibitor; inhibits platelet activation by selectively and reversibly blocking the active site of FXa without requiring a cofactor (eg, antithrombin III) for activity Inhibits free FXa, prothrombinase activity, and thrombin-induced platelet aggregation

Common side effects

Rash
Anemia
Abnormal LFTs
Interstitial lung disease

Boxed warnings

Reduced efficacy with CrCl >95 mL/min Do not use with CrCL >95 mL/min In the ENGAGE AF-TIMI 48 study, patients with NVAF with CrCL >95 mL/min had an increased rate of ischemic stroke with edoxaban 60 mg/day compared with patients treated with warfarin In these patients, another anticoagulant should be used Premature discontinuation increases risk for ischemic events Premature discontinuation of any oral anticoagulant in the absence of adequate alternative anticoagulation increases the risk of ischemic events If discontinued for a reason other than pathological bleeding or comp…